GioTag Final Data

Conclusions from the observational GioTag study were   published in Future OncologyiGiotrif/Gilotrif (afatinib) followed by osimertinib showed median overall survival (OS) of 37.6 months in patients with EGFR mutation-positive NSCLC
Source: Boehringer Ingelheim Corporate News - Category: Research Source Type: news